Skip to content
AI IntelligenceMay 9, 2026Primary Market
Article

Nektar Therapeutics · Undisclosed · Unbekannt

Nektar Therapeutics filed an 8-K reporting entry into a material definitive agreement, potentially related to a licensing deal or capital raise.

Data Cube AI EditorialSource: SEC EDGAR
01

Source Brief

Nektar Therapeutics filed an 8-K reporting entry into a material definitive agreement, potentially related to a licensing deal or capital raise.